Sofosbuvir improves HCV-induced insulin resistance by blocking IRS1 degradation

Clin Transl Med. 2021 Jan;11(1):e275. doi: 10.1002/ctm2.275.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / pharmacology*
  • Female
  • Hepatitis C / drug therapy*
  • Humans
  • Insulin Receptor Substrate Proteins / drug effects*
  • Insulin Resistance*
  • Male
  • Middle Aged
  • Sofosbuvir / pharmacology*
  • Treatment Outcome

Substances

  • Antiviral Agents
  • IRS1 protein, human
  • Insulin Receptor Substrate Proteins
  • Sofosbuvir